Clinical Trials
30 trialsA Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
SunRISe-5
Janssen Research & Development, LLC
MoonRISe-1
Janssen Research & Development, LLC
MoonRISe-3
Janssen Research & Development, LLC
BRIDGE
Eastern Cooperative Oncology Group
ADAPT-BLADDER
Hoosier Cancer Research Network
GAIN-BCG
Alliance for Clinical Trials in Oncology
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
BLATAM
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
BCG-TIME
Queen's University
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Memorial Sloan Kettering Cancer Center
HGNMIBC
Relmada Therapeutics, Inc.
COBRA
Medical University of Vienna
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer
Clinical Hospital Centre Zagreb
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
Al-Azhar University
POLO
University of Bern
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
RemeGen Co., Ltd.
BIC
Corewell Health West
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Aadi Bioscience, Inc.
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
Eli Lilly and Company